Aldeyra Therapeu Stock Price, News & Analysis

Aldeyra Therapeutics (NASDAQ: ALDX) announced a conference call on March 17, 2022, at 8:00 a.m. ET to discuss its financial results for the year ended December 31, 2021, along with recent corporate highlights. The call will be accessible via dial-in and a live webcast on the company’s website. Aldeyra is focused on developing therapies for immune-mediated diseases, with key candidates reproxalap in Phase 3 trials for dry eye disease and ADX-629 in Phase 2 trials for psoriasis and COVID-19. More information is available on their website.

Aldeyra Therapeutics (NASDAQ: ALDX) has initiated a Phase 2 clinical trial for ADX-2191, an investigational drug for treating retinitis pigmentosa (RP), a rare genetic eye disease affecting 82,000-110,000 individuals in the U.S. The trial will evaluate the safety and tolerability of ADX-2191 in eight patients with rhodopsin mutations. Results are expected in the second half of 2022. ADX-2191 has received orphan drug designation from the FDA, which provides various incentives including market exclusivity upon approval.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) will have its President and CEO, Todd C. Brady, M.D., Ph.D., participate in a fireside chat at the SVB Leerink 2022 Global Healthcare Conference. The discussion, moderated by Marc Goodman from SVB Leerink, will be available on demand starting at 9:20 a.m. ET on February 16, 2022. Interested parties can access the webcast through the Investors & Media section of Aldeyra's website, where it will remain archived for 90 days. Aldeyra focuses on innovative therapies for immune-mediated diseases with drug candidates like reproxalap and ADX-629 in clinical trials.

Aldeyra Therapeutics (ALDX) announced the publication of positive results from a Phase 2 clinical trial of reproxalap for allergic conjunctivitis in the journal Clinical Ophthalmology. The trial demonstrated that reproxalap significantly improves ocular itching, tearing, and redness compared to the vehicle. Conducted with 70 adults, the trial showed sustained symptom relief up to an hour post-exposure to allergens. Reproxalap is currently in Phase 3 trials for dry eye disease and allergic conjunctivitis, addressing a significant unmet need in treating these conditions.

Aldeyra Therapeutics (Nasdaq: ALDX) announced positive results from a Phase 2 clinical trial of reproxalap, a treatment for dry eye disease. The trial demonstrated statistically significant reductions in ocular discomfort (p=0.002) and itching (p=0.01) compared to Xiidra. Reproxalap, a novel RASP modulator, had no safety concerns reported. This data suggests reproxalap's potential as a first-line therapy. The trial included 56 patients and indicated improved tolerability over existing treatments, addressing compliance issues that often arise with current therapies.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced that Dr. Todd C. Brady will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference. The conversation will be available on demand starting at 7:00 a.m. ET on January 10, 2022. Aldeyra specializes in therapies for immune-mediated diseases, with products like reproxalap and ADX-629 in various clinical trial phases. Reproxalap is in Phase 3 trials for dry eye disease and allergic conjunctivitis, while ADX-629 is in Phase 2 trials for psoriasis and COVID-19. The webcast can be accessed on their website.

Aldeyra Therapeutics (ALDX) has completed enrollment for Part 1 of its Phase 3 GUARD Trial evaluating ADX-2191 for preventing proliferative vitreoretinopathy (PVR), an ocular disease with no approved therapies. The trial, involving 110 patients in the U.S., aims to assess recurrent retinal detachment rates post-surgery. Results are expected in the second half of 2022. ADX-2191, a methotrexate formulation, has received fast track and orphan drug designations from the FDA, potentially expediting development and offering market exclusivity.

Aldeyra Therapeutics announced the top-line results of its Phase 3 TRANQUILITY trial for reproxalap, aimed at treating dry eye disease. While the primary endpoint of ocular redness was not achieved, significant results were recorded for the secondary endpoint, the Schirmer test (p=0.0001). The upcoming TRANQUILITY-2 trial's primary endpoint has been adjusted, allowing for either Schirmer test or ocular redness to satisfy it, with enrollment targets increasing to 400 patients. A New Drug Application submission for dry eye disease is anticipated by mid-2022, contingent on the trial outcomes.

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), a biotechnology firm focused on immune-modulating therapies for ocular and systemic diseases, has announced CEO Todd C. Brady's participation in several upcoming investor conferences. These include the Berenberg US CEO Conference on November 10, the Eyecelerator@AAO 2021 on November 11, the Jefferies London Healthcare Conference on November 18, and Ophthalmology Day at BTIG on November 30. Webcasts of these events will be accessible on their Investors & Media page for 90 days.